Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma

Experimental and Molecular Pathology

Volumn 96, Issue 1, 2014, Pages 92-97

  Kapitanović, Sanja ^a   Čačev, Tamara ^a   Lončar, Božo ^b   Ivković, Tina Catela ^a   Križanac, Šimun ^b   Pavelić, Krešimir ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b University of Zagreb School of Medicine   (Croatia)

Author keywords

Colon adenocarcinoma; FHIT; Immunohistochemistry; LOH; MRNA

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FHIT GENE; GENE EXPRESSION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPORADIC COLON ADENOCARCINOMA; SURVIVAL TIME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

COLON ADENOCARCINOMA; FHIT; IMMUNOHISTOCHEMISTRY; LOH; MRNA;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; AGED; COLON; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MINISATELLITE REPEATS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892459104     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.12.005     Document Type: Article

References (30)

1. Ahsee K.W., Cooke T.G., Pickford I.R., Soutar D., Balmain A. An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res. 1994, 54:1617-1621.
2. Baffa R., Veronese M.L., Santoro R., Mandes B., Palazzo J.P., Rugge M., Santoro E., Croce C.M., Huebner K. Loss of FHIT expression in gastric carcinoma. Cancer Res. 1998, 58:4708-4714.
3. Barnes L.D., Garrison P.N., Siprashvili Z., Guranowski A., Robinson A.K., Ingram S.W., Croce C.M., Ohta M., Huebner K. FHIT, a putative tumor suppressor in humans, is a dinucleoside 5',5″-P1, P3-triphosphate hydrolase. Biochemistry 1996, 35:11529-11535.
4. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 1999, 59:3866-3869.
5. Cao J., Li W., Xie J., Du H., Tang W., Wang H., Chen X., Xiao W., Li Y. Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg. Oncol. 2006, 15:223-233.
6. Croce C.M., Sozzi G., Huebner K. Role of FHIT in human cancer. J. Clin. Oncol. 1999, 17:1618-1624.
7. Druck T., Hadaczek P., Fu T.B., Ohta M., Siprashvili Z., Baffa R., Negrini M., Kastury K., Veronese M.L., Rosen D., Rothstein J., McCue P., Cotticelli M.G., Inoue H., Croce C.M., Huebner K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 1997, 57:504-512.
8. Fong K.M., Biesterveld E.J., Virmani A., Wistuba I., Sekido Y., Bader S.A., Ahmadian M., Ong S.T., Rassool F.V., Zimmerman P.V., Giaccone G., Gazdar A.F., Minna J.D. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 1997, 57:2256-2267.
9. Hao X.P., Willis J.E., Pretlow T.G., Rao J.S., MacLennan G.T., Talbot I.C., Pretlow T.P. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res. 2000, 60:18-21.
10. Ishwad C.S., Ferrell R.E., Rossie K.N., Appel B.N., Johnson J.T., Myers E.N., Law J.C., Srivastava S., Gollin S.M. Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. Int. J. Cancer 1996, 69:1-4.
11. Kapitanović S., Cacev T., Berković M., Popović-Hadzija M., Radosević S., Seiwerth S., Spaventi S., Pavelić K., Spaventi R. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. J. Clin. Pathol. 2004, 57:1312-1318.
12. Lubinski J., Hadaczek P., Podolski J., Toloczko A., Sikorski A., McCue P., Druck T., Huebner K. Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res. 1994, 54:3710-3713.
13. Man S., Ellis I.O., Sibbering M., Blamey R.W., Brook J.D. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res. 1996, 56:5484-5489.
14. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., Hittelman W., Hong W.K. Frequent microsatellite alterations of chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med. 1996, 2:682-685.
15. McIver B., Grebe S.K., Wang L., Hay I.D., Yokomizo A., Liu W., Goellner J.R., Grant C.S., Smith D.I., Eberhardt N.L. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin. Endocrinol. 2000, 52:749-757.
16. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 1996, 56:3173-3179.
17. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., Huebner K. The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84:587-597.
18. Siprashvili Z., Sozzi G., Barnes L.D., McCue P., Robinson A.K., Eryomin V., Sard L., Tagliabue E., Greco A., Fusetti L., Schwartz G., Pierotti M.A., Croce C.M., Huebner K. Replacement of FHIT in cancer cells suppresses tumorigenecity. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13771-13776.
19. Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., Tornielli S., Pilotti S., De Gregorio L., Pastorino U., Pierotti M.A., Ohta M., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996, 85:17-26.
20. Sozzi G., Sard L., De Gregorio L., Marchetti A., Musso K., Buttitta F., Tornielli S., Pellegrini S., Veronese M.L., Manenti G., Incarbone M., Chella A., Angeletti C.A., Pastorino U., Huebner K., Bevilaqua G., Pilotti S., Croce C.M., Pierotti M.A. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 1997, 57:2121-2123.
21. Spaventi R., Pečur L., Pavelić K., Pavelić Z.P., Spaventi Š., Stambrook P.J. Human tumour bank in Croatia: a possible model for a small bank as a part of future European tumour bank network. Eur. J. Cancer 1994, 30A:419.
22. Thiagalingam S., Lisitsyn N.A., Hamaguchi M., Wigler M.H., Willson J.K., Markowitz S.D., Leach F.S., Kinzler K.W., Vogelstein B. Evaluation of the FHIT gene in colorectal cancers. Cancer Res. 1996, 56:2936-2939.
23. Tokuchi Y., Kobayashi Y., Hayashi S., Hayashi M., Tanimoto K., Hashimoto T., Nishida K., Ishikawa Y., Nakagawa K., Satoh Y., Yamamoto M., Tsuchiya E. Abnormal FHIT transcripts found in both lung cancer and normal lung tissue. Genes Chromosomes Cancer 1999, 24:105-111.
24. Virgilio L., Shuster M., Gollin S.M., Veronese M.L., Ohta M., Huebner K., Croce C.M. FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9770-9775.
25. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
26. Wang N., Perkins K.L. Involvement of band 3p14 in t (3;8) hereditary renal carcinoma. Cancer Genet. Cytogenet. 1984, 11:479-481.
27. Wierzbicki P.M., Adrych K., Kartanowicz D., Dobrowolski S., Stanislawowski M., Chybicki J., Godlewski J., Korybalski B., Smoczynski M., Kmiec Z. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer. J. Physiol. Pharmacol. 2009, 60:63-70.
28. Wu C.L., Sloan P., Read A.P., Harris R., Thakker N. Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res. 1994, 54:6484-6488.
29. Yasugi A., Yashima K., Hara A., Koda M., Kawaguchi K., Harada K., Andachi H., Murawaki Y. Fhit, Mlh1, p53 and phenotypic expression in the early stage of colorectal neoplasm. Oncol. Rep. 2008, 19:41-47.
30. Zöchbauer-Müller S., Fong K.M., Maitra A., Lam S., Geradts J., Ashfaq R., Virmani A.K., Milchgrub S., Gazdar A.F., Minna J.D. 5' CpG island methylation of the FHIT gene is correlated with the loss of gene expression in lung and breast cancer. Cancer Res. 2001, 61:3581-3585.